ClinicalTrials.gg
CompletedNCT06378697Updated Oct 16, 2026

A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

A Phase 3 interventional study of AK111 and Placebo+AK111 in Ankylosing Spondylitis, sponsored by Akeso. Completed at 60 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2023, registered Mar 2024).
Updated Oct 16, 20266 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
5th of 62
510 · median 150
Started
2023
with 6 others
Phase 3
18 of 76
4 open now
Registered
56th of 76
by date
Lead sponsor
2 of 76
Akeso

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 5th largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2023, is one of 18 in phase 3, and was the 56th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with active ankylosing spondylitis.

Read the detailed description

The study consists of 3 parts. Part 1 is screening period, Part 2 is Placebo control period and part 3 is Long term treatment follow-up period. The research period is 61 weeks in total.

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥18 years old.
  • Subjects with confirmed ankylosing spondylitis before screening.
  • During screening and before randomization, BASDAI score ≥ 4, total back pain score≥ 4.
  • Subjects received at least 2 kind of non-steroidal anti-inflammatory drugs (NSAIDs), prior to randomization with an inadequate response or failure to respond, or with or intolerance to the use of NSAIDs.
  • Subjects who are regularly taking NSAIDs, weak opioids or oral (The daily dose should be ≤10mg prednisone or equivalent dose of glucocorticoid) as part of their AS therapy are required to be on a stable dose for at least 14 days before randomization. If the drug has been discontinued, at least 2 weeks is required before randomization.
  • Subjects taking methotrexate (MTX) (≤25mg/week) or Sulfasalazine (≤3g/day) are allowed to continue their medication if started at least 12 weeks prior to baseline, with a stable dose for at least 4 weeks before randomization. If the drug has been discontinued, at least 4 weeks washout period is required before randomization.
  • Subjects who are able to understand and voluntarily sign the ICF and complete the study procedure.

Exclusion criteria

Exclusion Criteria:

  • Subjects with symptom of pain that affected the evaluation of efficacy.
  • Subjects with other inflammatory diseases or diseases except Ankylosing spondylitis (AS).
  • Subjects who are using strong opioid analgesics.
  • Received intramuscular or intravenous injection within 2 weeks prior to randomization; Received intraarticular or paraspinal glucocorticoid therapy within 4 weeks before randomization.
  • Received other antirheumatic drugs (except methotrexate, sulfasalazine), proprietary Chinese medicine or traditional Chinese medicine decoction, JAK inhibitor treatment for AS within 4 weeks before randomization.
  • Received Natalizumab or other B cell or T cell modulator in the 12 months prior to randomization.
  • Previous exposure to secukinumab, ixekizumab or any other biologic drug directly targeting IL-17 or IL-17 receptor.
  • Received multiple tumor necrosis factor α (TNF-α) inhibitors; The eluting period of biologics received before randomization is shorter than the protocol.
  • Participated in a clinical study of any other drug or medical device within 1 month (≤30 days) prior to randomization, or last received the drug within 5 half-lives.
  • The presence of any other systemic disease or laboratory abnormalities that the investigator has judged unsuitable for clinical trials.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (actual)

Study arms

  • Experimental
    AK111

    AK111 150 mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week 48.

    Drug: AK111

  • Placebo comparator
    placebo

    Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.

    Drug: Placebo+AK111

Interventions

  • DrugAK111

    Drug: AK111 subcutaneous injection at week 0,1, 4 and 4-weekly thereafter until week 48.

  • DrugPlacebo+AK111

    Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.

06

What researchers measure

Primary outcomes

  1. the response rate of ASAS20

    Percentage of subjects who achieve Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response at Week 16.

    Time frame: week 16

Secondary outcomes

  1. The response rate of ASAS40

    Percentage of subjects who achieve Assessment of SpondyloArthritis International Society 40% improvement (ASAS40) response at Week 16.

    Time frame: week 16

  2. The response rate of ASAS20

    Percentage of subjects who achieve ASAS20 response throughout the clinical trial

    Time frame: baseline to week 52

  3. The response rate of ASAS40

    Percentage of subjects who achieve ASAS40 response throughout the clinical trial

    Time frame: baseline to week 52

  4. The response rate of ASAS5/6

    Percentage of subjects who achieve ≥20% improvement in five of the six domains (ASAS5/6) response throughout the clinical trial

    Time frame: baseline to week 52

  5. Change from baseline on the ASDAS-CRP

    Change from baseline on the Ankylosing Spondylitis Disease Activity Score based on CRP (ASDAS-CRP) at each visit from baseline

    Time frame: baseline to week 52

  6. Change from baseline on the SF-36 PCS

    Change from baseline on the Short-Form 36 physical component score(SF-36 PCS) at each visit from baseline

    Time frame: baseline, week 16 and week 52

  7. Change from baseline on the ASQoL scores

    Change from baseline on the Ankylosing Spondylitis Quality of Life (ASQoL) scores at each visit from baseline

    Time frame: baseline, week 16 and week 52

  8. Treatment-emergent adverse events

    Percentage of subjects with treatment-emergent adverse events (TEAEs) during the study

    Time frame: baseline to week 52

  9. Serious adverse events

    Percentage of subjects with treatment-emergent serious adverse events (SAEs) during the study

    Time frame: baseline to week 52

  10. Clinically significant examination results

    Recording clinically significant examination results

    Time frame: baseline to week 52

07

Study locations

60 sites
  • 1006-The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
  • 1038-Anhui Provincial Hospital
    Hefei, Anhui, China
  • 1001-Peking University Third Hospital
    Beijing, Beijing Municipality, China
  • 1002-Xuanwu Hospital Capital Medical University
    Beijing, Beijing Municipality, China
  • 1042-Peking University Shougang Hospital
    Beijing, Beijing Municipality, China
  • 1061-Beijing Tiantan Hospital
    Beijing, Beijing Municipality, China
  • 1049-The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • 1027-Lanzhou University Second Hospital
    Lanzhou, Gansu, China
  • 1005-Nanfang Hospital
    Guangzhou, Guangdong, China
  • 1025-Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
  • 1030-Jieyang People's Hospital
    Jieyang, Guangdong, China
  • 1008-The Seventh Affiliated Hospital, Sun Yat-sen University
    Shenzhen, Guangdong, China
  • 1026-Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • 1056-Zhongshan Traditional Chinese Medicine Hospital
    Zhongshan, Guangdong, China
  • 1060-The First Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
  • 1024-Liuzhou People's Hospital
    Liuzhou, Guangxi, China
  • 1021-The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi, China
  • 1057-The Second Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
  • 1022-The First Affiliated Hospital of Hainan Medical University
    Haikou, Hainan, China
  • 1034-Affiliated Hospital of Hebei University
    Baoding, Hebei, China
  • 1012-Hebei Petro China Central Hospital
    Langfang, Hebei, China
  • 1029-Hebei General Hospital
    Shijiazhuang, Hebei, China
  • 1033-The First Hospital of Qiqihar
    Qiqihar, Heilongjiang, China
  • 1045-The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
  • 1053-Nanyang Central Hospital
    Nanyang, Henan, China
  • 1051-Shiyan People's Hospital
    Shiyan, Hubei, China
  • 1031-The First Affiliated Hospital of University of South China
    Hengyang, Hunan, China
  • 1032-Yueyang Central Hospital
    Yueyang, Hunan, China
  • 1011-Zhuzhou Central Hospital
    Zhuzhou, Hunan, China
  • 1017-Changzhou NO.2 People's Hospital
    Changzhou, Jiangsu, China
  • 1037-The Second People's Hospital of Lianyungang
    Lianyungang, Jiangsu, China
  • 1004-Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
  • 1007-Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
  • 1036-Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • 1018-Affiliated Hospital of Nantong University
    Nantong, Jiangsu, China
  • 1035-Wuxi People's Hospital
    Wuxi, Jiangsu, China
  • 1013-Xuzhou Central Hospital
    Xuzhou, Jiangsu, China
  • 1014-Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • 1047-The First Affiliated Hospital of Gannan Medical College
    Ganzhou, Jiangxi, China
  • 1020-The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • 1039-The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • 1046-Pingxiang People's Hospital
    Pingxiang, Jiangxi, China
  • 1044-Jilin Provincial People's Hospital
    Changchun, Jilin, China
  • 1028- Jining First People's Hospital
    Jining, Shandong, China
  • 1058-Affiliated Hospital of Jining Medical University
    Jining, Shandong, China
  • 1019-Linyi City People Hospital
    Linyi, Shandong, China
  • 1062-Qilu Hospital (Qingdao), Shandong University
    Qingdao, Shandong, China
  • 1055-Weifang People's Hospital
    Weifang, Shandong, China
  • 1016-Zaozhuang Municipal Hospital
    Zaozhuang, Shandong, China
  • 1054-Linfen Central Hospital
    Linfen, Shanxi, China
  • 1009-Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • 1043-Yuncheng Central Hospital
    Yuncheng, Shanxi, China
  • 1010-West China Hospital,Sichuan University
    Chengdu, Sichuan, China
  • 1048-Mianyang Central Hospital
    Mianyang, Sichuan, China
  • 1041-Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan, China
  • 1059-Tianjin First Central Hospital
    Tianjin, Tianjin Municipality, China
  • 1023-The People's Hospital of Xinjiang Uyghur Autonomous Region
    Ürümqi, Xinjiang, China
  • 1040- Huzhou Third People's Hospital
    Huzhou, Zhejiang, China
  • 1015-Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang, China
  • 1050-The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Feb 2025, 14 months.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 14 months is below that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Apr 22, 2024
StartActual
Nov 22, 2023
Primary completionActual
Feb 19, 2025
CompletionActual
Nov 7, 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added
Show 6 added (6 China)
  • 1061-Beijing Tiantan Hospital · Beijing, China
  • 1060-The First Affiliated Hospital of Guilin Medical University · Guilin, China
  • 1057-The Second Affiliated Hospital of Guangxi Medical University · Nanning, China
  • 1058-Affiliated Hospital of Jining Medical University · Jining, China
  • 1062-Qilu Hospital (Qingdao), Shandong University · Qingdao, China
  • 1059-Tianjin First Central Hospital · Tianjin, China
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    6 sites added
    Show 6 added (6 China)
    • 1061-Beijing Tiantan Hospital · Beijing, China
    • 1060-The First Affiliated Hospital of Guilin Medical University · Guilin, China
    • 1057-The Second Affiliated Hospital of Guangxi Medical University · Nanning, China
    • 1058-Affiliated Hospital of Jining Medical University · Jining, China
    • 1062-Qilu Hospital (Qingdao), Shandong University · Qingdao, China
    • 1059-Tianjin First Central Hospital · Tianjin, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06378697
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Nov 22, 2023
Primary completion
Feb 19, 2025
Completion
Nov 7, 2025
Last update
Oct 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gumokimab

Start the discussion